Keytruda Is Key To The Merck Thesis, Goldman Sachs Says In Upgrade
April 23, 2018 at 10:34 AM EDT
The Merck & Co., Inc. (NYSE: MRK) story has slowly captivated analysts, and on Monday the pharmaceutical company corralled Goldman ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.